Form 4: Director William Jones Receives Apogee Therapeutics Options

Apogee Therapeutics director William A. Jones Jr. was granted 7,657 stock options as part of his compensation package.

Summary

• Director William A. Jones Jr. received a grant of 7,657 stock options for Apogee Therapeutics, Inc. (APGE) common stock.
• The options have an exercise price of $85.00 per share.
• The grant date for these options is June 9, 2026.
• The options are scheduled to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new stock options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future performance of the company's common stock price exceeding the $85.00 exercise price.

Future Outlook

The options vest on the one-year anniversary of the grant date, June 9, 2027, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure alignment between board members and shareholders.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for publicly traded biotech companies.
• The grant size is typical for non-employee director compensation packages in mid-cap pharmaceutical firms.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of the 7,657 stock options on June 9, 2027.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Options, Director Compensation